Research ExplorerPublicationsTecovirimat for the treatment of severe Mpox in Germany

Tecovirimat for the treatment of severe Mpox in Germany

Standard

Tecovirimat for the treatment of severe Mpox in Germany. / Hermanussen, Lennart; Brehm, Thomas Theo; Wolf, Timo; Boesecke, Christoph; Schlabe, Stefan; Borgans, Frauke; Monin, Malte B; Jensen, Björn-Erik Ole; Windhaber, Stefan; Scholten, Stefan; Jordan, Sabine; Lütgehetmann, Marc; Wiesch, Julian Schulze Zur; Addo, Marylyn M; Mikolajewska, Agata; Niebank, Michaela; Schmiedel, Stefan.

In: INFECTION, Vol. 51, No. 5, 10.2023, p. 1563-1568.

Research output: SCORING: Contribution to journal › Short publication › Research › peer-review

Harvard

Hermanussen, L, Brehm, TT, Wolf, T, Boesecke, C, Schlabe, S, Borgans, F, Monin, MB, Jensen, B-EO, Windhaber, S, Scholten, S, Jordan, S, Lütgehetmann, M, Wiesch, JSZ, Addo, MM, Mikolajewska, A, Niebank, M & Schmiedel, S 2023, 'Tecovirimat for the treatment of severe Mpox in Germany', INFECTION, vol. 51, no. 5, pp. 1563-1568. https://doi.org/10.1007/s15010-023-02049-0

APA

Hermanussen, L., Brehm, T. T., Wolf, T., Boesecke, C., Schlabe, S., Borgans, F., Monin, M. B., Jensen, B-E. O., Windhaber, S., Scholten, S., Jordan, S., Lütgehetmann, M., Wiesch, J. S. Z., Addo, M. M., Mikolajewska, A., Niebank, M., & Schmiedel, S. (2023). Tecovirimat for the treatment of severe Mpox in Germany. INFECTION, 51(5), 1563-1568. https://doi.org/10.1007/s15010-023-02049-0

Vancouver

Hermanussen L, Brehm TT, Wolf T, Boesecke C, Schlabe S, Borgans F et al. Tecovirimat for the treatment of severe Mpox in Germany. INFECTION. 2023 Oct;51(5):1563-1568. https://doi.org/10.1007/s15010-023-02049-0

Bibtex

@article{8bebc729534e46e4833fad0ad346daf8,
title = "Tecovirimat for the treatment of severe Mpox in Germany",
abstract = "BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus.METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms.RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution.CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.",
author = "Lennart Hermanussen and Brehm, {Thomas Theo} and Timo Wolf and Christoph Boesecke and Stefan Schlabe and Frauke Borgans and Monin, {Malte B} and Jensen, {Bj{\"o}rn-Erik Ole} and Stefan Windhaber and Stefan Scholten and Sabine Jordan and Marc L{\"u}tgehetmann and Wiesch, {Julian Schulze Zur} and Addo, {Marylyn M} and Agata Mikolajewska and Michaela Niebank and Stefan Schmiedel",
note = "Brief Report",
year = "2023",
month = oct,
doi = "10.1007/s15010-023-02049-0",
language = "English",
volume = "51",
pages = "1563--1568",
journal = "INFECTION",
issn = "0300-8126",
publisher = "Urban und Vogel",
number = "5",

}

RIS

TY - JOUR

T1 - Tecovirimat for the treatment of severe Mpox in Germany

AU - Hermanussen, Lennart

AU - Brehm, Thomas Theo

AU - Wolf, Timo

AU - Boesecke, Christoph

AU - Schlabe, Stefan

AU - Borgans, Frauke

AU - Monin, Malte B

AU - Jensen, Björn-Erik Ole

AU - Windhaber, Stefan

AU - Scholten, Stefan

AU - Jordan, Sabine

AU - Lütgehetmann, Marc

AU - Wiesch, Julian Schulze Zur

AU - Addo, Marylyn M

AU - Mikolajewska, Agata

AU - Niebank, Michaela

AU - Schmiedel, Stefan

N1 - Brief Report

PY - 2023/10

Y1 - 2023/10

N2 - BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus.METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms.RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution.CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.

AB - BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus.METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms.RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution.CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.

U2 - 10.1007/s15010-023-02049-0

DO - 10.1007/s15010-023-02049-0

M3 - Short publication

C2 - 37273167

VL - 51

SP - 1563

EP - 1568

JO - INFECTION

JF - INFECTION

SN - 0300-8126

IS - 5

ER -